{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:58:43Z","timestamp":1785279523993,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2025\u201318-73"],"award-info":[{"award-number":["320.6750.2025\u201318-73"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fuzuloparib, a novel PARP inhibitor, has demonstrated efficacy in patients with HER2-negative metastatic breast cancer (MBC) harboring germline BRCA1\/2 mutations. The addition of apatinib, an anti-angiogenic agent, enhances treatment outcomes. However, the economic value of these strategies remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the cost-utility of fuzuloparib with or without apatinib compared with standard chemotherapy in patients with HER2-negative metastatic breast cancer with germline BRCA mutations from the Chinese healthcare system perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A partitioned survival model was developed over a 10-year time horizon. Clinical inputs were derived from the phase III FABULOUS trial. Survival data were reconstructed and extrapolated using parametric models. Costs and utilities were obtained from published literature and Yaozh databases. Outcomes were measured in quality-adjusted life years (QALYs) and incremental cost-utility ratios (ICURs). A willingness-to-pay (WTP) threshold of \u00a5199,330\/QALY was applied. Deterministic and probabilistic sensitivity analyses were conducted to assess model uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the base-case analysis, total costs were \u00a5266,989.27 for fuzuloparib plus apatinib (FA), \u00a5230,151.42 for fuzuloparib monotherapy (FM), and \u00a5188,774.18 for standard chemotherapy (SC). Corresponding QALYs were 1.5669, 1.4128, and 1.1477, respectively. Compared with SC, the ICURs were \u00a5186,581.80 per QALY for FA and \u00a5156,081.63 per QALY for FM, both lower than the WTP threshold. Compared with FM, the ICUR was \u00a5239,051.59 per QALY for FA. Sensitivity analyses confirmed that the probability of the FA, FM and SC being cost-effective were 29.15%, 42.72%, and 28.13% at the WTP threshold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From the perspective of the Chinese healthcare system, both fuzuloparib plus apatinib and fuzuloparib monotherapy is cost-effective compared with standard chemotherapy at current WTP threshold. However, FA was not cost-effective relative to FM at the current Chinese WTP threshold.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1897783","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:10:30Z","timestamp":1785276630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1\/2 mutations: a cost-utility analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yitian","family":"Lang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shanghai Second People\u2019s Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Second People\u2019s Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.34172\/ijhpm.2020.244","article-title":"Methods for the economic evaluation of health care interventions for priority setting in the health system: an update from WHO CHOICE","volume":"1","author":"Bertram","year":"2021","journal-title":"Int. J. Health Policy Manag."},{"key":"B2","doi-asserted-by":"publisher","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","article-title":"Hypoxia-induced down-regulation of BRCA1 expression by E2Fs","volume":"65","author":"Bindra","year":"2005","journal-title":"Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working Group-6","volume":"32","author":"Briggs","year":"2012","journal-title":"Med. Decis. Mak."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.1158\/0008-5472.CAN-10-2352","article-title":"Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment","volume":"70","author":"Chan","year":"2010","journal-title":"Cancer Res."},{"key":"B7","unstructured":"Yaozh database\n          \n          \n          2026"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S1470-2045(13)70567-9","article-title":"Breast cancer in China","volume":"15","author":"Fan","year":"2014","journal-title":"Lancet Oncol."},{"key":"B9","article-title":"Markov models for health economic evaluation: the R package heemod","author":"Filipovi\u0107-Pierucci","year":"2017","journal-title":"ArXiv e-prints"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1864488","DOI":"10.3389\/fphar.2026.1864488","article-title":"Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China","volume":"17","author":"Fu","year":"2026","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published kaplan-meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v070.i08","article-title":"Flexsurv: a platform for parametric survival modeling in R","volume":"70","author":"Jackson","year":"2016","journal-title":"J. Stat. Softw."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0343330","DOI":"10.1371\/journal.pone.0343330","article-title":"Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China","volume":"21","author":"Kang","year":"2026","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1495082","DOI":"10.3389\/fphar.2024.1495082","article-title":"Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis","volume":"15","author":"Lang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(25)00523-6","article-title":"Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1\/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1616826","DOI":"10.3389\/fphar.2025.1616826","article-title":"Ramucirumab plus paclitaxel as switch maintenance in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer: a cost-effectiveness analysis","volume":"16","author":"Luo","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70259","DOI":"10.1002\/cncr.70259","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first\u2010line treatment for unresectable hepatocellular carcinoma: a cost\u2010effectiveness analysis","volume":"132","author":"Luo","year":"2026","journal-title":"Cancer"},{"key":"B24","volume-title":"The Fifth National Physical Fitness Survey Bulletin","year":"2026"},{"key":"B25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13058-020-01349-9","article-title":"Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study","volume":"22","author":"O\u2019Shaughnessy","year":"2020","journal-title":"Breast Cancer Res."},{"key":"B26","volume-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"key":"B27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/jrsm.1362","article-title":"Estimating hazard ratios from published kaplan-meier survival curves: a methods validation study","volume":"10","author":"Saluja","year":"2019","journal-title":"Res. Syn. Meth"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0278460","DOI":"10.1371\/journal.pone.0278460","article-title":"Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany","volume":"17","author":"Schwarz","year":"2022","journal-title":"PLoS ONE"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0207993","DOI":"10.1371\/journal.pone.0207993","article-title":"Global treatment costs of breast cancer by stage: a systematic review","volume":"13","author":"Sun","year":"2018","journal-title":"PLoS ONE"},{"key":"B31","unstructured":"A package for survival analysis in R\n          \n          \n            \n              Therneau\n              T. M.\n            \n          \n          \n          2020"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/cas.13947","article-title":"Pharmacologic characterization of fluzoparib, a novel poly(ADP \u2010Ribose) polymerase inhibitor undergoing clinical trials","volume":"110","author":"Wang","year":"2019","journal-title":"Cancer Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharp.2026.03.003","article-title":"Comments on the 2025 edition of China guidelines for pharmacoeconomic evaluations","volume":"2","author":"Wu","year":"2026","journal-title":"Pharmacoeconomics Policy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.2147\/OTT.S172305","article-title":"Progress in the treatment of solid tumors with apatinib: a systematic review","volume":"11","author":"Zhao","year":"2018","journal-title":"OTT"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3760\/cma.j.cn112338-20240129-00048","article-title":"Disease burden and economic burden of breast cancer in females in China: a synthesis analysis","volume":"45","author":"Zhou","year":"2024","journal-title":"Chin. J. Epidemiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1068463","DOI":"10.3389\/fonc.2023.1068463","article-title":"Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+\/HER2-advanced breast cancer - a Chinese healthcare system perspective","volume":"13","author":"Zhu","year":"2023","journal-title":"Front. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"104693","DOI":"10.1016\/j.breast.2026.104693","article-title":"Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+\/HER2-advanced breast cancer","volume":"85","author":"Zhu","year":"2026","journal-title":"Breast"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1897783\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:10:33Z","timestamp":1785276633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1897783\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":37,"alternative-id":["10.3389\/fphar.2026.1897783"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1897783","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1897783"}}